Back
Developing New Small Molecular Drugs for Prostate Cancer Therapy
Tzu-Min Chan, Horng-Jyh Harn, Tzyy-Wen Chiou, Shinn-Zong Lin
J. Cancer Ther. Vol.4 No.4, April 30, 2013  DOI: 10.4236/jct.2013.44A009
       (PDF  85K)     HTML      XML
Future Directions in Metastatic Castration Resistant Prostate Cancer (mCRPC): Clinical Rationale and Use of New-Generation Hormonal Therapies
Paolo Grassi, Elena Verzoni, Rosanna Montone, Isabella Testa, Enrico Garanzini, Pamela Biondani, Sara Pusceddu, Filippo de Braud, Giuseppe Procopio
J. Cancer Ther. Vol.4 No.3, May 23, 2013  DOI: 10.4236/jct.2013.43085
       (PDF  134K)     HTML      XML
Outcome of Combination Chemotherapy with Docetaxel, Estramustine Phosphate, and Carboplatin after Docetaxel and Prednisolone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Ryuichi Ito, Shintaro Narita, Hiroshi Tsuruta, Kazuyuki Numakura, Atsushi Maeno, Mitsuru Saito, Takamitsu Inoue, Norihiko Tsuchiya, Shigeru Satoh, Tomonori Habuchi
J. Cancer Ther. Vol.7 No.7, June 30, 2016  DOI: 10.4236/jct.2016.77049
       (PDF  511K)     HTML      XML
Upfront Docetaxel with LH-RH Antagonist for Metastatic Hormone Sensitive Prostate Cancer Considering Epithelial to Mesenchymal Transition
Teiichiro Aoyagi, Isao Kuroda, Go Nagao
Open J. Urol. Vol.10 No.11, November 13, 2020  DOI: 10.4236/oju.2020.1011033
       (PDF  482K)     HTML      XML
Synergy between molecular biology and imaging science toward mechanism-based biomarkers associated with prostate cancer
Belinda Seto
J. Biomed. Sci. Eng. Vol.5 No.12, December 31, 2012  DOI: 10.4236/jbise.2012.512A107
       (PDF  254K)     HTML      XML
 
 
Top